May 18, 2012

HELIX BIOPHARMA CORP. RECEIVES REGULATORY APPROVAL TO CONDUCT A EUROPEAN PHASE III CLINICAL TRIAL OF TOPICAL INTERFERON ALPHA-2B IN PATIENTS WITH LOW-GRADE CERVICAL LESIONS (PDF)

AURORA, Ontario, May 18, 2012 – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), a developer of biopharmaceutical drug candidates for the prevention and treatment of cancer, today announced that the German regulatory authority, the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte; “BfArM”), has approved Helix’s clinical trial application for a European Phase III efficacy trial of Topical Interferon Alpha-2b in patients with low-grade cervical lesions